Microsatellite stable disease, CDKN2A/2B deletion, BRCA2 E1035*, KRAS Q61R, TP53 S16* were all confirmed via somatic testing with a Tumor mutational burden (TMB) of 4. This evidence concerns the gene BRCA2 and neoplasm.